MARKET

INAB

INAB

In8Bio, Inc.
NASDAQ
1.470
+0.090
+6.52%
After Hours: 1.470 0 0.00% 16:10 06/17 EDT
OPEN
1.400
PREV CLOSE
1.380
HIGH
1.470
LOW
1.390
VOLUME
22.55K
TURNOVER
--
52 WEEK HIGH
2.730
52 WEEK LOW
1.170
MARKET CAP
14.48M
P/E (TTM)
-0.4830
1D
5D
1M
3M
1Y
5Y
1D
Weekly Report: what happened at INAB last week (0608-0612)?
Weekly Report · 2d ago
12 Health Care Stocks Moving In Thursday's After-Market Session
Benzinga · 6d ago
Weekly Report: what happened at INAB last week (0601-0605)?
Weekly Report · 06/08 10:34
Analysts Conflicted on These Healthcare Names: Tenaya Therapeutics (TNYA), IN8bio (INAB) and Veeva Systems (VEEV)
TipRanks · 06/04 10:50
IN8bio Publishes Nature Communications Review Highlighting Engineered γδ T Cell Cancer Therapies And Combination Treatment Advances
Benzinga · 06/03 12:39
Analysts Offer Insights on Healthcare Companies: Revolution Medicines (RVMD), IN8bio (INAB) and PolyPid (PYPD)
TipRanks · 06/01 15:10
IN8bio posts corporate deck highlighting gamma-delta T-cell therapy platform for autoimmune disease, cancer
PUBT · 06/01 14:35
IN8bio announces updated INB-200, INB-400 study data
TipRanks · 06/01 14:11
More
About INAB
IN8bio, Inc. is a clinical-stage biopharmaceutical company. The Company is focused on the discovery, development and commercialization of gamma-delta T cell-based immunotherapies for cancer patients. Gamma-delta T cells are a specialized population of T cells that possess properties, including the ability to differentiate between healthy and diseased tissue. Its lead program, INB-100, is in an ongoing investigator-sponsored Phase I clinical trial of acute myeloid leukemia (AML). Its other product candidates include INB-200, INB-300, INB-500 and INB-600. INB-200 is a genetically modified, autologous gamma-delta T cell product to be administered in combination with the current standard-of-care chemotherapy in newly diagnosed glioblastoma (GBM). INB-300 is a preclinical program focused on developing unique non-signaling gamma-delta T cell based chimeric antigen receptor (nsCAR)-enabled DeltEx product candidates with a focus on targeting liquid tumors and extracranial solid tumors.

Webull offers IN8bio Inc stock information, including NASDAQ: INAB real-time market quotes, financial reports, professional analyst ratings, in-depth charts, corporate actions, INAB stock news, and many more online research tools to help you make informed decisions. Trade stocks for 0 commission and 0 contract fees on the web version for easy and convenient access, or download the Webull app and trade on the go.

You can practice and explore trading INAB stock methods without spending real money on the virtual paper trading platform.